KU-0063794 is a novel, potent, cell permeable and selective inhibitor of mTOR (mammalian target of rapamycin) with potential anticancer activity.

3BDO is a butyrolactone analog which acts as a mTOR activator, it targets FKBP1A and activate the mTOR signaling pathway.

AZD8055 is a novel, potent selective, and orally bioavailable ATP-competitive mTOR (mammalian target of rapamycin) inhibitor with potential anticancer activity.

NV-5138 (NV 5138; NV5138) is a novel, selective, orally bioactive and brain/CNS-active mTORC1 (mammalian target of rapamycin complex 1) activator.

Everolimus (formerly also known as RAD001, SDZ-RAD, or the 40-O-(2-hydroxyethyl) derivative of sirolimus) is a potent and orally bioavailable inhibitor of mammalian target of rapamycin (mTOR) with immunosuppressive activity.

Rapamycin (also known as Sirolimus; AY-22989), a natural macrocyclic lactone isolated from the bacterium Streptomyces hygroscopicus, is a specific and potent mTOR inhibitor with IC50 of ~0.1 nM in HEK293 cells.

Sapanisertib (NK-128; MLN-0128; TAK-228) is a novel, potent, orally bioavailable and selective inhibitor of mTOR (mammalian target of rapamycin) with potential anticancer activity.

Temsirolimus (also known as CCI-779, NSC-683864; Torisel), an ester analog of rapamycin, is a potent and specific inhibitor of mTOR (mammalian target of rapamycin) with potential anticancer activity.

Onatasertib (CC-223; CC223) is a potent, selective, and orally bioavailable inhibitor of mTOR (mammalian target of rapamycin) kinase with anticancer activity.

WAY-600 (WAY600) is a novel, potent, ATP-competitive and selective inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity.